

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Single Technology Appraisal (STA)

## Mannitol dry powder for inhalation for the treatment of cystic fibrosis

## Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Pharmaxis (mannitol dry powder for inhalation)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Children</li> <li>• Action for Sick Children</li> <li>• Afiya Trust</li> <li>• Association for Children with Life Threatening or Terminal Conditions</li> <li>• Black Health Agency</li> <li>• British Lung Foundation</li> <li>• Carers UK</li> <li>• Children's Society</li> <li>• Chinese National Healthy Living Centre</li> <li>• Cystic Fibrosis Trust</li> <li>• Equalities National Council</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• National Children's Bureau</li> <li>• National Parent Partnership Network</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• WellChild</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Respiratory Nurse Specialists</li> <li>• British Thoracic Society</li> <li>• Chartered Society of Physiotherapy</li> <li>• Primary Care Respiratory Society UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Association of British Healthcare Industries</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• EUCOMED</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• Public Health Wales NHS Trust</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• Roche Products (Dornase Alfa)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• School of Health &amp; Related Research Sheffield (SchARR)</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Paediatrics &amp; Child Health</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• NHS Calderdale</li> <li>• Department of Health</li> <li>• Sandwell PCT</li> <li>• Welsh Assembly Government</li> </ul>	<p><u>Associated Guideline Group</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> <li>• National Collaborating Centre for Women and Children’s Health</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.